November 2014 - The Reporter
The event will explore a future of health care that “is going to be anchored in the metaverse” and be the first such symposium to be held both live and in the metaverse itself, according to Rubin Pillay, M.D., Ph.D., executive director of the Marnix E. Heersink Institute for Biomedical Innovation.
Is your monitor too low or keyboard too high? Get your workspace set up right and learn the risks of cumulative trauma with UAB’s online Office Ergonomics Awareness Course.
Published in Be Healthy
Executive director Brian Atkinson is working to reassess the post-pandemic demand for parking and modernize campus transportation services.

The UA System Board of Trustees elevated three former faculty to emeritus status during its Feb. 3 meeting. Those honored were Pamela S. Murray, Stephen James O’Connor and George Howard.

Published in Awards & Honors
Your baby will have 2 injections, which will be 8 weeks apart. You will be asked to return to the study site with your baby up to 7 times over the course of 15 months. Your baby will be closely monitored by the study team if any symptoms of COVID-19 are reported at any time throughout their participation. Nasal swabs and blood draws will be required at 3-4 of the study site visits. Compensation for participation is available. To learn more, visit BabyCOVEStudy.com or contact the UAB study team: 205-638-2629 or mlpurser@uabmc.edu
Published in Clinical Trials

The University of Alabama System Board of Trustees voted to appoint one chair and three professors to endowed positions during its Feb. 3 meeting. Those honored are Jeffery Walker, Lewis Shi, Farah Lubin and Brant Wagener.

Published in Achievements
The University of Alabama at Birmingham (UAB), in collaboration with Novo Nordisk, is conducting a 3-year research study to see if CagriSema, an investigational weekly medicine being studied for the treatment of obesity is also safe for the heart and blood vessels.

We are doing this study to see if CagriSema (Cagrilintide/semaglutide), a new medicine intended for the treatment of obesity, is safe for use in people living with obesity and cardiovascular disease. The study will also include some people with type 2 diabetes and/or chronic kidney disease.

You may qualify to participate if::
  • You have had a stroke, a heart attack (myocardial infarction), or have poor circulation (peripheral
  • arterial disease)
  • You are 55 years of age or older
  • You are living with obesity (BMI ≥ 30 kg/m2 )
  • You can have type 2 diabetes and/or chronic kidney disease
  • You are able to attend regular clinic visits and receive phone calls over
  • a period of 3 years

Want to know more about the REDEFINE 3 study?
Call the study team at (205) 996-4015 or via email ccnrn@uab.edu
Published in Clinical Trials

Tatyana Gavrikova, Sherry Polhill and Aparna Tamhane are the fourth-quarter 2022 honorees of the UAB Shared Values in Action Program, which honors those whose work exemplifies and embodies Forging the Future's shared values. Nominations for first-quarter 2023 honorees are open through Feb. 28.

Published in Awards & Honors

Take a look at new technologies being studied at UAB for treatment of depression, sleep apnea, traumatic brain injury and tic disorders.

UAB continues to implement its Campus Master Plan through new facilities and renovations to enhance instruction, research, technology and student life. Some are under construction and others are in planning stages; these include an update to the Unity Park green space, seven new buildings and a new parking deck.

Published in Campus News
Page 34 of 351